ClinicalTrials.gg
Not yet recruitingNCT07891533Updated Oct 23, 2026

Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera

A Phase 2 interventional study of Epetraborole and Placebo in Polycythemia Vera (SNOMED CT: 109992005), sponsored by AN2 Therapeutics, Inc. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by AN2 Therapeutics, Inc · Phase 2, Interventional, and Treatment

Updated Oct 23, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Polycythemia Vera with a site in Australia — 6 open to participants now, 9 under way, 3 of them phase 3. Polycythemia Vera · Australia.

Planned enrollment
12th of 20
75 · median 94
Started
2026
with 4 others
Phase 2
6 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
AN2 Therapeutics, Inc

Among the 21 studies in Polycythemia Vera with a site in Australia, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, and was the 21st registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

6 of the 21 studies in Polycythemia Vera with a site in Australia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Polycythemia Vera with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 2 trial to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of oral epetraborole tablets for the treatment of adults with phlebotomy-dependent polycythemia vera (PV). The trial is designed to confirm the safety profile of oral epetraborole in the PV patient population and to identify 1 or more oral epetraborole doses for the treatment of phlebotomy-dependent PV. The study consists of an open-label Sentinel Cohort, an open-label Dose Selection Cohort (Part 1), followed by a double-blind, randomized, Placebo-Controlled Cohort (Part 2), and an optional Open-Label Extension (OLE) Cohort (Part 3)

03

Conditions studied

  • Polycythemia Vera (SNOMED CT: 109992005)

Keywords

  • Hematologic disease
  • Bone marrow disease
  • Myeloproliferative disorder
  • Bone Marrow Neoplasms
  • Hematologic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Hemic and Lymphatic Diseases
  • Polycythemia Vera
  • Epetraborole
  • Benzoxaborole
  • Boron
  • Phase 2[
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to read and provide written prior to the performance of any trial-specific procedures and willing to follow the protocol requirements
  2. Aged 18 to 75 years (inclusive) at Screening
  3. A confirmed diagnosis of PV according to ICC (Thiele, 2023), including /Hct level, EPO level, and JAK2 mutation status assessed by analysis of peripheral blood sampling
  4. Documented positive JAK2 V617F (exon 14) or JAK2 exon 12 mutation
  5. Hct \<45% at Screening
  6. Has records of all phlebotomies performed for at least 28 weeks (preferably up to 52 weeks) prior to Day 1
  7. Phlebotomy-dependent, defined as at least 3 phlebotomies during the 28 weeks prior to Day 1, including a phlebotomy within 8 weeks prior to Screening
  8. Either receiving OR not receiving cytoreductive therapy for PV, as follows:

    1. Participants who are not currently receiving cytoreductive therapy must have either never received it or been discontinued from it for at least 24 weeks prior to Day 1 and any AEs due to cytoreductive therapy have either recovered or are ≤ Grade 1 prior to Day 1
    2. Participants currently receiving cytoreductive therapy with HU, interferon, or busulfan must have received such therapy for at least 24 weeks prior to Day 1 and have been on a stable or decreasing dose for at least 8 weeks prior to Day 1, and with no planned change in dose during the trial
  9. score of 0, 1, or 2
  10. If FOCP

    1. Must not be currently breastfeeding
    2. If sexually active with a male partner: Must be either sexually abstinent or agree to use at least 2 medically accepted, effective methods of from Screening through at least 1 week after the last dose of trial intervention
    3. Must have a negative urine pregnancy test at Screening and on Day 1; the Day 1 urine test will be confirmed by a serum pregnancy test.
  11. Male participants who are sexually active with an FOCP must agree to use an effective barrier method of contraception from Screening through at least 1 week after the last dose of trial intervention
  12. Agrees to not donate sperm (males) or ova (females) from Screening through at least 1 week after the last dose of trial intervention

Exclusion criteria

Exclusion Criteria

  1. History of arterial or venous thrombosis (eg, deep vein thrombosis or splenic vein thrombosis) within 24 weeks prior to Day 1
  2. History of major bleeding events and/or a requirement for blood transfusion therapy due to bleeding in the 6 months prior to Day 1
  3. Meets the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (Tefferi, 2023)
  4. >1000 × 109/L, WBC count >25 × 109/L; or presence of any blast cells in peripheral blood at Screening
  5. Diagnosis of secondary polycythemia
  6. Prior, concomitant, or planned therapy with ruxolitinib
  7. Received any drug within 6 weeks prior to Day 1 or 5 half-lives (whichever is longer) prior to Day 1 or has not recovered from adverse effects of prior administration of any investigational agent
  8. Prior exposure to epetraborole; drug intolerance or to any compound from the same class as epetraborole
  9. History of prior drug-induced pneumonitis
  10. Severe hepatic impairment at Screening as evidenced by clinical signs of cirrhosis or end-stage hepatic disease
  11. Liver disease or liver injury at Screening as evidenced by:

    1. or AST >3 ×
    2. Total >2 × ULN
  12. \<30 mL/min/1.73 m2 at Screening
  13. Current skin or history of clinically significant skin cancer within 5 years prior to Day 1
  14. Known history of:

    1. or C infection
    2. infection plus either an active AIDS-defining illness or a known \<200/mm3 within 12 months prior to Day 1
  15. Known primary or secondary immunodeficiency defined as the following:

    1. Primary immunodeficiency: rare, inherited genetic disorders, leading to frequent, severe, or unusual infections, issues, and a higher cancer risk
    2. Secondary immunodeficiency: acquired deficiencies, including those from chemotherapy/ drugs, certain cancers (like leukemia/lymphoma), severe malnutrition, major burns/trauma, and other chronic conditions. These are common and result from environmental influences or diseases, unlike primary ones that are genetic.
  16. Any other condition, prior therapy, or clinically significant co-morbidity at Screening that would, in the Investigator's opinion, interfere with the participant's ability to participate in the entire trial, pose a risk to the participant, or constitute a potentially confounding medical condition, including the following:

    1. Uncontrolled hypertension >160/100 mmHg
    2. Uncontrolled diabetes mellitus ( level of ≥9%)
    3. Class III/IV heart failure
    4. Severe coronary artery disease, including unstable angina or myocardial infarction in the 12 months prior to Screening, or likely to require invasive procedure(s) to manage their CAD during the trial
    5. Symptomatic CVD or recent stroke within 12 months prior to Screening or active CVD with symptomatic transient events
    6. Non-cutaneous malignancy requiring treatment
  17. Any major surgical procedure requiring general anesthesia within 1 month prior to Day 1 or planned elective surgery during the trial
  18. Prior or concomitant therapy within 4 weeks prior to Day 1, or expected during the trial, with the following:

    1. Drugs known to consistently produce myelosuppression: oxazolidinone antibiotics , chloramphenicol, mTORC inhibitors
    2. Drugs that can inhibit ADH: some H2-receptor antagonists (eg, cimetidine, famotidine, ranitidine), pyrazoles (fomepizole)
    3. Drugs that inhibit ALDH: disulfiram, isoniazid, ketoconazole, certain cephalosporins , first-generation sulfonylureas
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Sentinel Cohort

    Open Label Fixed Dose Epetraborole

    Drug: Epetraborole

  • Experimental
    Part 1: Dose Selection Cohort

    Open Label Epetraborole Dose Selection

    Drug: Epetraborole

  • Experimental
    Part 2: Epetraborole (Double Blind)

    Fixed Dose Epetraborole

    Drug: Epetraborole

  • Placebo comparator
    Part 2: Placebo (Double Blind Randomized Withdrawal)

    Placebo Control

    Drug: Placebo

  • Experimental
    Part 3: Open Label Extension Cohort (Optional)

    Open Label Epetraborole

    Drug: Epetraborole

Interventions

06

What researchers measure

Primary outcomes

  1. Part 2: Proportion of Participants per Treatment Group Maintaining Clinical Success defined as hematocrit control, not undergoing therapeutic phlebotomy and completing 12 weeks of treatment in Part 2

    Time frame: Week 29 - Week 40

07

Study locations

1 site
  • 501001
    Perth, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Apr 2029, 29 months later.

Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2026
First posted
Oct 23, 2026
StartEst.
Nov 2026
Primary completionEst.
Apr 2029
CompletionEst.
Jun 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07891533
Lead sponsor
AN2 Therapeutics, Inc
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Nov 2026 (estimated)
Primary completion
Apr 2029 (estimated)
Completion
Jun 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Cameron Trenor
Contact
trials@an2therapeutics.com
650-331-9090 ext. 700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion